Method of treating endometreosis

• US 20050079156A1
• Filed: 10/29/2002
• Published: 04/14/2005
• Est. Priority Date: 11/06/2001
• Status: Abandoned Application

• Current Assignee: Laboratoires Serono SA
• Original Assignee: Laboratoires Serono SA
• Inventors: Eshkol, Aliza, Wong, Grace
• Application Number:
  US10/494,699
• Publication Number:
  US 20050079156A1
• Time in Patent Office: Days
• US Class Current: 424/85.600
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/217 IFN-gamma
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to the treatment of a woman for endometriosis comprising the administration of IFN-gamma, a cytokine antagonist and/or an anti-estrogenic agent.

Claims

1. A method of treating a woman suffering from or susceptible to endometriosis, comprising administering to the woman an effective amount of interferon-gamma (IFN-γ

).

2. A method of treating a woman suffering from or susceptible to endometriosis, comprising administering to the woman an effective amount of a cytokine antagonist.

16. The method of claim 2, wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.

3. A method of treating a woman suffering from or susceptible to endometriosis comprising administering a therapeutically effective amount of a combination of IFN-γ

and a cytokine antagonist.

17. The method of claims 3, wherein the cytokine antagonist is an antagonist to tumor necrosis factor.

22. The method of claim 3, wherein the cytokine antagonist is selected from the group consisting of antagonist to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.

4. A method of treating a woman suffering from or susceptible to endometriosis comprising administering a therapeutically effective amount of IFN-γ

in combination with an anti-estrogenic agent.

7. The method of claim 4, wherein the anti-estrogenic agent is an aromatase inhibitor.

5. A method of treating a woman suffering from or susceptible to endometriosis comprising administering a therapeutically effective amount of a cytokine antagonist in combination with an anti-estrogenic agent.

18. The method of claim 5, wherein the anti-estrogenic agent is an aromatase inhibitor.

20. The method of claims 5, wherein the cytokine antagonist is an antagonist to tumor necrosis factor.

23. The method of claim 5, wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.

6. A method of treating a woman suffering from or susceptible to endometriosis comprising administering a therapeutically effective amount of IFN-γ

and a cytokine antagonist in combination with an anti-estrogenic agent.

19. The method of claim 6, wherein the anti-estrogenic agent is an aromatase inhibitor.

21. The method of claims 6, wherein the cytokine antagonist is an antagonist to tumor necrosis factor.

24. The method of claim 6, wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.

8-12. -12. (canceled)

13. An article of manufacture comprising:

i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing endometriosis in a woman; and

ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises IFN-γ

together with a pharmaceutical acceptable carrier

14. An article of manufacture comprising:

i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing endometriosis in a woman; and

ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises a cytokine antagonist together with a pharmaceutical acceptable carrier

25. The method of claim 14, wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.

15. An article of manufacture comprising:

i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing endometriosis in a woman; and

ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises a combination of IFN-γ and

a cytokine antagonist together with a pharmaceutical acceptable carrier

26. The method of claim 15, wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.